ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Impact of APOE4-related dementia risk in underrepresented groups from the All of Us research program.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Association of coronary artery bypass with cognitive impairment in coronary artery disease across APO (ε) genotypes in AllofUS.medRxiv : the preprint server for health sciences · 2026Article
- Association of coronary artery bypass with cognitive impairment in coronary artery disease across APO (ε) genotypes in AllofUS.BMJ neurology open · 2026Article
- The contribution of apolipoprotein E genetic variation to dementia risk in British South Asians.Brain communications · 2026Article
- Impact of APOE4-related dementia risk in underrepresented groups from the All of Us research program.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
introductionLongitudinal electronic health records (EHRs), "dementia" diagnostic codes, and genetic data from All of Us were used to see if there is a higher risk of dementia and an attenuated impact of apolipoprotein ε4 (APOE4) on Alzheimer's disease (AD) risk in Black and Hispanic/Latino groups.
methodsParticipants included 9,784 Hispanic/Latinos, 14,937 Non-Hispanic Blacks (NHB), and 60,388 Non-Hispanic Whites (NHWs) ≥age 60 without an initial dementia diagnosis.
resultsThere was a significantly higher risk of developing a dementia diagnosis in Hispanic/Latino and NHB participants than NHW participants and comparably increased dementia hazard ratios in the Hispanic/Latino, NHB, and NHW APOE4 carriers than non-carriers (hazard ratio [HR] [95% confidence interval {CI}] 1.54 [1.25-1.91], 1.25 [1.00-1.57], and 1.55 [1.40-1.72]). DISCUSSION: Compared to NHW individuals, Hispanic/Latino and NHB individuals are at higher risk of developing a "dementia diagnosis" and comparably higher risk in APOE4 carriers than non-carriers. Plasma AD biomarkers could clarify the proportion of dementia cases with and without AD and the impact of APOE4 on AD in these groups. HIGHLIGHTS: Hispanic/Latino and non-Hispanic Black individuals have a higher risk of all-cause dementia. The impact of apolipoprotein ε4 (APOE4) on dementia risk was similar in the studied ethnoracial groups. Plasma biomarkers could inform the risk of Alzheimer's disease (AD) and impact of APOE4 in these groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.